1. Home
  2. DOUG vs CRBU Comparison

DOUG vs CRBU Comparison

Compare DOUG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

N/A

Current Price

$1.57

Market Cap

145.4M

Sector

Real Estate

ML Signal

N/A

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$0.43

Market Cap

138.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DOUG
CRBU
Founded
1911
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.4M
138.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DOUG
CRBU
Price
$1.57
$0.43
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $5.75
AVG Volume (30 Days)
555.6K
★ 3.8M
Earning Date
11-17-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 118.68
3.64
EPS
★ N/A
N/A
Revenue
★ $955,578,000.00
N/A
Revenue This Year
$0.59
$114.75
Revenue Next Year
$7.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.38
$0.41
52 Week High
$3.03
$2.49

Technical Indicators

Market Signals
Indicator
DOUG
CRBU
Relative Strength Index (RSI) 49.85 27.27
Support Level $1.55 N/A
Resistance Level $1.65 $0.58
Average True Range (ATR) 0.09 0.04
MACD 0.01 0.03
Stochastic Oscillator 52.78 13.25

Price Performance

Historical Comparison
DOUG
CRBU

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: